News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,818 Results
Type
Article (14262)
Company Profile (105)
Press Release (259443)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88275)
Career Advice (465)
Deals (15391)
Drug Delivery (73)
Drug Development (36714)
Employer Resources (50)
FDA (6382)
Job Trends (6232)
News (150703)
Policy (14129)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23318)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6573)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32018)
Collaboration (726)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33461)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38980)
Executive appointments (528)
FDA (7480)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (166)
GLP-1 (440)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3575)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (413)
MASH (68)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9898)
Metabolic disorders (435)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (228)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29745)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13518)
Phase 3 (12211)
Pipeline (1904)
Policy (135)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2659)
Recruiting (18)
Regulatory (10955)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (704)
Last 365 days (10406)
2026 (951)
2025 (10714)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20070)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12422)
2013 (10594)
2012 (11396)
2011 (11922)
2010 (10890)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20890)
Australia (2687)
California (3177)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40879)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1447)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12669)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,818 Results for "terns pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.
December 9, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN-601.
October 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - February 2, 2026
February 3, 2026
·
1 min read
Press Releases
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
January 5, 2026
·
1 min read
Press Releases
Terns Pharmaceuticals to Participate in the 2025 Jefferies Global Healthcare Conference in London
November 17, 2025
·
1 min read
Press Releases
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
·
7 min read
Press Releases
Terns Announces Proposed Public Offering
December 10, 2025
·
5 min read
Earnings
Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market
Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.
August 6, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 10, 2025
·
9 min read
Press Releases
Terns Announces Pricing of Upsized $650 Million Public Offering
December 10, 2025
·
5 min read
1 of 27,382
Next
